HCC: VEGFR-TKIs alone or in combination with immune checkpoint inhibitors

December 06, 2023 00:29:56
HCC: VEGFR-TKIs alone or in combination with immune checkpoint inhibitors
COR2ED - Oncology Medical Conversation
HCC: VEGFR-TKIs alone or in combination with immune checkpoint inhibitors

Dec 06 2023 | 00:29:56

/

Show Notes

In this medical education podcast episode, Prof. Peter Galle and Prof. Amit Singal discuss the use of VEGFR-TKIs in the treatment of advanced or unresectable HCC and explain the immunomodulation rationale to combine it with immune checkpoint inhibitor.

Combination approach has been validated recently with the atezolizumab+bevacizumab combination being the new standard of care in 1L setting for advanced HCC patients. In the context of advanced HCC, both experts share their view about the dosing approach with VEGFR-TKI and provide insight to handle the dosing when combining with PD-1 inhibitor.

Both experts reiterate that biomarkers are urgently needed in HCC and summarize the current stratification of patients used to predict the response with VEGFR-TKI monotherapy or in immunotherapy combination. Finally, they emphasize that pre-habilitation of HCC patients is key to make the HCC patient fit for the best available treatment option.

Other Episodes

Episode

December 06, 2023 00:19:43
Episode Cover

Prostate cancer: PARP inhibitors. Part 2 - Combination therapy; US and EU perspectives

Dr Neal Shore, Uro-Oncologist and Chief Medical Officer for Genesis Care and Urology and Surgical Oncology in the United States and Dr Elena Castro,...

Listen

Episode

November 25, 2024 00:23:25
Episode Cover

Testing to treatment of BRAF-mutant metastatic NSCLC

 Testing to treatment of BRAF-mutant metastatic NSCLC    In this educational podcast episode, experts Prof. David Planchard and Dr Federico Cappuzzo discuss the significance of...

Listen

Episode

September 30, 2025 00:21:56
Episode Cover

Exploring the role of targeted radiopharmaceutical treatment in NETs

How are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key...

Listen